[1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer[J]. Cancer Immunol Immunother, 2021, 70(3): 607-617.
|
[3] |
Mardis ER. Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response[J]. Genome Med, 2019, 11(1): 71.
|
[4] |
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322.
|
[5] |
Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment[J]. Nat Rev Immunol, 2015, 15(11): 669-682.
|
[6] |
Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2017, 547(7662): 217-221.
|
[7] |
Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial[J]. Nature, 2019, 565(7738): 234-239.
|
[8] |
Mcgranahan N, Swanton C. Clonal heterogeneity andtumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
|
[9] |
Castro A, Ozturk K, Pyke RM, et al. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes[J]. BMC Med Genomics, 2019, 12(Suppl 6): 107.
|
[10] |
Benvenuto M, Focaccetti C, Izzi V, et al. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer[J]. Semin Cancer Biol, 2021, 72: 65-75.
|
[11] |
Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution[J]. Nature, 2019, 567(7749): 479-485.
|
[12] |
Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma[J]. Int J Cancer, 1997, 71(2): 142-147.
|
[13] |
Mcdonald KA, Kawaguchi T, Qi Q, et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients[J]. Ann Surg Oncol, 2019, 26(7): 2191-2199.
|
[14] |
Kondo Y, Fukuyama T, Yamamura R, et al. Detection of KK-LC-1 protein, a cancer/testis antigen, in patients with breast cancer[J]. Anticancer Res, 2018, 38(10): 5923-5928.
|
[15] |
Egland KA, Kumar V, Duray P, et al. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers[J]. Mol Cancer Ther, 2002, 1(7): 441-450.
|
[16] |
Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy[J]. Mol Cancer, 2019, 18(1): 128.
|
[17] |
Zhang X, Kim S, Hundal J, et al. Breast cancer neoantigens can induce CD8(+) T-cell responses and antitumor immunity[J]. Cancer Immunol Res, 2017, 5(7): 516-523.
|
[18] |
Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach[J]. Expert Rev Vaccines, 2013, 12(10): 1211-1217.
|
[19] |
González FE, Gleisner A, Falcón-Beas F, et al. Tumor cell lysates as immunogenic sources for cancer vaccine design[J]. Hum Vaccin Immunother, 2014, 10(11): 3261-3269.
|
[20] |
Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives[J]. Nat Rev Clin Oncol, 2011, 9(1): 16-32.
|
[21] |
Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States military cancer institute clinical trials group study I-04[J]. Cancer, 2010, 116(2): 292-301.
|
[22] |
Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US military cancer institute clinical trials group study I-01 and I-02[J]. Cancer, 2012, 118(10): 2594-2602.
|
[23] |
Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors[J]. Cancer Res, 1998, 58(21): 4902-4908.
|
[24] |
Knutson KL, Schiffman K, Cheever MA, et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity[J]. Clin Cancer Res, 2002, 8(5): 1014-1018.
|
[25] |
Mittendorf EA, Ardavanis A, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase Ⅱ trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence[J]. Oncotarget, 2016, 7(40): 66 192-66 201.
|
[26] |
Li WH, Li YM. Chemical strategies to boost cancer vaccines[J]. Chem Rev, 2020, 120(20): 11 420-11 478.
|
[27] |
Lopes A, Bastiancich C, Bausart M, et al. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models[J]. J Immunother Cancer, 2021, 9(4):e001243.
|
[28] |
Pollard A J, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines[J]. Nat Rev Immunol, 2009, 9(3): 213-220.
|
[29] |
Heery CR, Ibrahim NK, Arlen PM, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial[J]. JAMA Oncol, 2015, 1(8): 1087-1095.
|
[30] |
Dissanayake D, Murakami K, Tran MD, et al. Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant[J]. PLoS One, 2014, 9(3): e92380.
|
[31] |
Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines[J]. Semin Immunol, 2010, 22(3): 132-143.
|
[32] |
Liu W, Tang H, Li L, et al. Peptide-based therapeutic cancer vaccine: Current trends in clinical application[J]. Cell Prolif, 2021,54(5): e13025.
|
[33] |
Supabphol S, Li L, Goedegebuure SP, et al. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy[J]. Expert Opin Investig Drugs, 2021,30(5): 1-13.
|
[34] |
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J]. Nat Commun, 2019, 10(1): 5408.
|
[35] |
Bradley JD, Nishio M, Okamoto I, et al. PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage Ⅲ NSCLC[J]. J Clin Oncol, 2019, 37(suppl 15): 8573.
|
[36] |
Singer CF, Pfeiler G, Hubalek M, et al. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase Ⅱ study (ABCSG 34)[J]. Eur J Cancer, 2020, 132: 43-52.
|
[37] |
Vassilaros S, Tsibanis A, Tsikkinis A, et al. Up to 15-year clinical follow-up of a pilot phase Ⅲ immunotherapy study in stage Ⅱ breast cancer patients using oxidized mannan-MUC1[J]. Immunotherapy, 2013, 5(11): 1177-1182.
|
[38] |
Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase Ⅰ/Ⅱ clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients[J]. Ann Oncol, 2014, 25(9): 1735-1742.
|
[39] |
Chamani R, Ranji P, Hadji M, et al. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis[J]. Eur J Pharmacol, 2018, 831: 87-93.
|
[40] |
Zhang W, Lu X, Cui P, et al. Phase Ⅰ/Ⅱ clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer[J]. Cancer Immunol Immunother, 2019, 68(1): 121-130.
|
[41] |
Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer[J]. Clin Cancer Res, 2011, 17(22): 7164-7173.
|
[42] |
Takahashi R, Toh U, Iwakuma N, et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients[J]. Breast Cancer Res, 2014, 16(4): 70.
|
[43] |
Toh U, Sakurai S, Saku S, et al. Early phase Ⅱ study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer[J]. Cancer Sci, 2020, 111(8): 2760-2769.
|
[44] |
Tiriveedhi V, Tucker N, Herndon J, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer[J]. Clin Cancer Res, 2014, 20(23): 5964-5975.
|
[45] |
Miles D, Roché H, Martin M, et al. Phase Ⅲ multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer[J]. Oncologist, 2011, 16(8): 1092-1100.
|
[46] |
Ibrahim NK, Murray JL, Zhou D, et al. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial[J]. J Cancer, 2013, 4(7): 577-584.
|
[47] |
Bertucci F, Ng CKY, Patsouris A, et al. Genomic characterization of metastatic breast cancers[J]. Nature, 2019, 569(7757): 560-564.
|
[48] |
Armistead PM. Cellular therapy against public neoantigens[J]. J Clin Invest, 2019, 129(2): 506-508.
|
[49] |
Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade[J]. Cell Rep, 2017, 18(1): 248-262.
|